18 Nov. 2020

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100

Today marks the start of the World Antimicrobial Awareness Week 2020 by the WHO, underlining once more the incredibly important health emergency that...


01 Sep. 2020

BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candid...


14 Juli 2020

BioVersys and Partners from Lille Sign Long-term Collaboration Agreement Creating a Unique Cross-Border AMR Cluster in Antimicrobial Research Excellence

BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration agreeme...


23 Juni 2020

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of a fixed combination of BVL-GSK098 and ETH

Basel, Switzerland. June, 23rd, 2020. 09:00 CEST BioVersys develops BVL-GSK098, in collaboration with GSK, as an entirely new mechanism to poten...